325 related articles for article (PubMed ID: 22710916)
1. γ-Secretase modulator in Alzheimer's disease: shifting the end.
Xia W; Wong ST; Hanlon E; Morin P
J Alzheimers Dis; 2012; 31(4):685-96. PubMed ID: 22710916
[TBL] [Abstract][Full Text] [Related]
2. Interacting with γ-secretase for treating Alzheimer's disease: from inhibition to modulation.
Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Logroscino G; Santamato A; Greco A; Seripa D; Pilotto A
Curr Med Chem; 2011; 18(35):5430-47. PubMed ID: 22087836
[TBL] [Abstract][Full Text] [Related]
3. Γ-secretase modulators do not induce Aβ-rebound and accumulation of β-C-terminal fragment.
Li T; Huang Y; Jin S; Ye L; Rong N; Yang X; Ding Y; Cheng Z; Zhang J; Wan Z; Harrison DC; Hussain I; Hall A; Lee DH; Lau LF; Matsuoka Y
J Neurochem; 2012 Apr; 121(2):277-86. PubMed ID: 22035227
[TBL] [Abstract][Full Text] [Related]
4. First and second generation γ-secretase modulators (GSMs) modulate amyloid-β (Aβ) peptide production through different mechanisms.
Borgegard T; Juréus A; Olsson F; Rosqvist S; Sabirsh A; Rotticci D; Paulsen K; Klintenberg R; Yan H; Waldman M; Stromberg K; Nord J; Johansson J; Regner A; Parpal S; Malinowsky D; Radesater AC; Li T; Singh R; Eriksson H; Lundkvist J
J Biol Chem; 2012 Apr; 287(15):11810-9. PubMed ID: 22334705
[TBL] [Abstract][Full Text] [Related]
5. Orally bioavailable and brain-penetrant pyridazine and pyridine-derived γ-secretase modulators reduced amyloidogenic Aβ peptides in vivo.
Huang Y; Li T; Eatherton A; Mitchell WL; Rong N; Ye L; Yang XJ; Jin S; Ding Y; Zhang J; Li Y; Wu Y; Jin Y; Sang Y; Cheng Z; Browne ER; Harrison DC; Hussain I; Wan Z; Hall A; Lau LF; Matsuoka Y
Neuropharmacology; 2013 Jul; 70():278-86. PubMed ID: 23485401
[TBL] [Abstract][Full Text] [Related]
6. A canine model to evaluate efficacy and safety of γ-secretase inhibitors and modulators.
Borghys H; Tuefferd M; Van Broeck B; Clessens E; Dillen L; Cools W; Vinken P; Straetemans R; De Ridder F; Gijsen H; Mercken M
J Alzheimers Dis; 2012; 28(4):809-22. PubMed ID: 22072214
[TBL] [Abstract][Full Text] [Related]
7. Advances in the identification of γ-secretase inhibitors for the treatment of Alzheimer's disease.
D'Onofrio G; Panza F; Frisardi V; Solfrizzi V; Imbimbo BP; Paroni G; Cascavilla L; Seripa D; Pilotto A
Expert Opin Drug Discov; 2012 Jan; 7(1):19-37. PubMed ID: 22468891
[TBL] [Abstract][Full Text] [Related]
8. γ-secretase modulators and presenilin 1 mutants act differently on presenilin/γ-secretase function to cleave Aβ42 and Aβ43.
Okochi M; Tagami S; Yanagida K; Takami M; Kodama TS; Mori K; Nakayama T; Ihara Y; Takeda M
Cell Rep; 2013 Jan; 3(1):42-51. PubMed ID: 23291095
[TBL] [Abstract][Full Text] [Related]
9. Independent generation of Abeta42 and Abeta38 peptide species by gamma-secretase.
Czirr E; Cottrell BA; Leuchtenberger S; Kukar T; Ladd TB; Esselmann H; Paul S; Schubenel R; Torpey JW; Pietrzik CU; Golde TE; Wiltfang J; Baumann K; Koo EH; Weggen S
J Biol Chem; 2008 Jun; 283(25):17049-54. PubMed ID: 18426795
[TBL] [Abstract][Full Text] [Related]
10. BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease.
Scannevin RH; Chollate S; Brennan MS; Snodgrass-Belt PA; Peng H; Xu L; Jung MY; Bussiere T; Arastu MF; Talreja T; Xin Z; Dunstan RW; Fahrer D; Rohde E; Dunah AW; Wang J; Kumaravel G; Taveras AG; Moore Arnold H; Rhodes KJ
Neuropharmacology; 2016 Apr; 103():57-68. PubMed ID: 26690893
[TBL] [Abstract][Full Text] [Related]
11. Development and mechanism of γ-secretase modulators for Alzheimer's disease.
Crump CJ; Johnson DS; Li YM
Biochemistry; 2013 May; 52(19):3197-216. PubMed ID: 23614767
[TBL] [Abstract][Full Text] [Related]
12. Novel γ-secretase modulators: a review of patents from 2008 to 2010.
Pettersson M; Kauffman GW; am Ende CW; Patel NC; Stiff C; Tran TP; Johnson DS
Expert Opin Ther Pat; 2011 Feb; 21(2):205-26. PubMed ID: 21231889
[TBL] [Abstract][Full Text] [Related]
13. Discovery of γ-secretase modulators with a novel activity profile by text-based virtual screening.
Zettl H; Ness J; Hähnke V; Beher D; Jumpertz T; Saric A; Baumann K; Pietrzik CU; Bulic B; Schneider G; Weggen S
ACS Chem Biol; 2012 Sep; 7(9):1488-95. PubMed ID: 22725102
[TBL] [Abstract][Full Text] [Related]
14. TASTPM mice expressing amyloid precursor protein and presenilin-1 mutant transgenes are sensitive to γ-secretase modulation and amyloid-β₄₂ lowering by GSM-10h.
Hussain I; Harrison DC; Hawkins J; Chapman T; Marshall I; Facci L; Ahmed S; Brackenborough K; Skaper SD; Mead TL; Smith BB; Giblin GM; Hall A; Gonzalez MI; Richardson JC
Neurodegener Dis; 2011; 8(1-2):15-24. PubMed ID: 20689247
[TBL] [Abstract][Full Text] [Related]
15. Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production.
Wanngren J; Ottervald J; Parpal S; Portelius E; Strömberg K; Borgegård T; Klintenberg R; Juréus A; Blomqvist J; Blennow K; Zetterberg H; Lundkvist J; Rosqvist S; Karlström H
J Biol Chem; 2012 Sep; 287(39):32640-50. PubMed ID: 22851182
[TBL] [Abstract][Full Text] [Related]
16. Advances in gamma-secretase modulation.
Pissarnitski D
Curr Opin Drug Discov Devel; 2007 Jul; 10(4):392-402. PubMed ID: 17659480
[TBL] [Abstract][Full Text] [Related]
17. An improved cell-based method for determining the γ-secretase enzyme activity against both Notch and APP substrates.
McKee TD; Loureiro RM; Dumin JA; Zarayskiy V; Tate B
J Neurosci Methods; 2013 Feb; 213(1):14-21. PubMed ID: 23219895
[TBL] [Abstract][Full Text] [Related]
18. γ-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes.
Imbimbo BP; Giardina GA
Curr Top Med Chem; 2011; 11(12):1555-70. PubMed ID: 21510832
[TBL] [Abstract][Full Text] [Related]
19. Combining an amyloid-beta (Aβ) cleaving enzyme inhibitor with a γ-secretase modulator results in an additive reduction of Aβ production.
Strömberg K; Eketjäll S; Georgievska B; Tunblad K; Eliason K; Olsson F; Radesäter AC; Klintenberg R; Arvidsson PI; von Berg S; Fälting J; Cowburn RF; Dabrowski M
FEBS J; 2015 Jan; 282(1):65-73. PubMed ID: 25303711
[TBL] [Abstract][Full Text] [Related]
20. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]